Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma
| Autor: | Adam Yakovich, Courtney L Erskine, Roxana S. Dronca, Eric P. Grewal, Lisa A. Kottschade, Wendy K. Nevala, Matthew S. Block, Svetomir N. Markovic, Jacob B Allred, Carrie A Strand, Robert R. McWilliams |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Agonist Adult Male medicine.medical_specialty medicine.drug_class medicine.medical_treatment T cell Immunology Gastroenterology 03 medical and health sciences 0302 clinical medicine Glucosides Internal medicine medicine Immunology and Allergy Humans Adverse effect Melanoma Aged Aged 80 and over business.industry Immunogenicity Water Immunotherapy Middle Aged medicine.disease Vaccination 030104 developmental biology medicine.anatomical_structure Lipid A Oncology 030220 oncology & carcinogenesis Vaccines Subunit Peptide vaccine Emulsions Female business |
| Zdroj: | Immunotherapy. 12(13) |
| ISSN: | 1750-7448 |
| Popis: | Aim: We tested the safety and immunogenicity of a novel vaccine in patients with resected high-risk melanoma. Patients & methods: HLA-A2-positive patients with resected Stage II–IV melanoma were randomized to receive up to three vaccinations of melanoma-associated peptide (MART-1a) combined with a stable oil-in-water emulsion (SE) either with the Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA-SE–Schedule 1) or alone (SE–Schedule 2). Safety and immunogenicity of the vaccines were monitored. Results: A total of 23 patients were registered. No treatment-related grade 3 or higher adverse events were observed. Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively. Conclusion: Both vaccine schedules were well-tolerated and resulted in an increase in MART-1a-specific T cells. Clinical Trial registration: NCT02320305 ( ClinicalTrials.gov ). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|